Patent 9175045 was granted and assigned to Aileron Therapeutics on November, 2015 by the United States Patent and Trademark Office.
Biologically active crosslinked polypeptides with improved properties relative to their corresponding precursor polypeptides, having good cell penetration properties and reduced binding to human proteins; and methods of identifying and making such improved polypeptides.